12:00 AM
 | 
Sep 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bavituximab: Completed Phase II enrollment

Peregrine completed enrollment of 31 patients in the second stage of an open-label, Indian Phase II trial evaluating 3 mg/kg IV bavituximab given weekly in combination with carboplatin and paclitaxel given on...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >